29 results
424B7
RLAY
Relay Therapeutics Inc
16 Nov 23
Prospectus with selling stockholder info
4:16pm
, we announced additional interim clinical data for RLY-4008 with a data cut-off date of August 1, 2022 that was presented at the European Society … . In June 2023, we presented complete first-in-human dose escalation data for RLY-4008 at the 2023 American Society of Clinical Oncology Annual Meeting
8-K
RLAY
Relay Therapeutics Inc
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
consistent with the analysis reported by the Company at the European Society for Medical Oncology Congress 2022.
Most treatment-related adverse
8-K
EX-99.1
660yurq
8 Aug 23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:14pm
8-K
t3gk ja0xefn7
25 May 23
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
5:05pm
8-K
EX-99.1
mvcmc7dn57a2bt344k
25 May 23
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
5:05pm
8-K
EX-99.1
6g7be31b1
4 May 23
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
4:10pm
8-K
EX-99.1
zl0btm
3 Nov 22
Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
4:11pm
424B5
kguc386ur7uju
13 Sep 22
Prospectus supplement for primary offering
5:19pm
424B5
bdty lc86n5yqe
12 Sep 22
Prospectus supplement for primary offering
7:35am
8-K
EX-99.1
h60yled8297
12 Sep 22
Enrollment for the pivotal cohort anticipated to be completed in the second half of 2023
6:05am
8-K
2fevq7ozfi38t7ox03g
12 Sep 22
Enrollment for the pivotal cohort anticipated to be completed in the second half of 2023
6:05am
8-K
po6njd
8 Sep 22
Regulation FD Disclosure
6:31am
8-K
EX-99.1
lit409uf7wqercjlul
4 Aug 22
Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
4:32pm